The recent surge in investments into niche pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for revolutionary treatments and significant returns is undeniable, the associated risks are also notable. Many of